Menu

Primary Menu

Skip to content
  • Home
  • About Shift
  • Shift’s Focus
  • Shift’s Technology
  • Shift News
Show Header Sidebar Content
Twitter Email LinkedIn

Shift Pharmaceuticals

Shift News

Our Recent Updates

FDA grants Orphan Drug status for Shift’s lead compound for SMA – May 2020

Shift Pharmaceuticals partners with CMT Research Foundation to further research CMT1A
treatment – February 2020

The Gwendolyn Strong Foundation and National Institute of Health fund Shift Pharmaceuticals – December 2019

Congressional Directed Medical Research Program (CDMRP) awards grant to Shift for the company’s lead compound for SMA – November 2018

Shift’s News

  • FDA grants Orphan Drug status for Shift’s lead compound for SMA May 14, 2020

Follow Us

Twitter Email LinkedIn

Footer Menu

Skip to content
  • Home
  • About Shift
  • Shift’s Focus
  • Shift’s Technology
  • Shift News
Copyright © 2022 Shift Pharmaceuticals. All Rights Reserved.
Scroll Up
  • Home
  • About Shift
  • Shift’s Focus
  • Shift’s Technology
  • Shift News